Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria [Yahoo! Finance]
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) [Yahoo! Finance]